Should liver enzymes be checked in a patient taking niacin?
Metadata[+] Show full item record
No randomized trials directly address the question of frequency of liver enzyme monitoring with niacin use. Niacin use is associated with early and late hepatotoxicity (strength of recommendation [SOR]: B, based on incidence data from randomized controlled trials and systematic reviews of cohort studies). Long-acting forms of niacin (Slo-Niacin) are more frequently associated with hepatotoxicity than the immediate-release (Niacor, Nicolar) or extended-release (Niaspan) forms (SOR: B, based on 1 randomized controlled trial and systematic reviews of cohort studies).
Journal of Family Practice, 54(3) 2005: 265-268.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.